Vaxcyte, Inc. PCVX
At closeNov 3, 2026, 5:14 PM EST
After hours · Nov 3, 5:14 PM ET
- YTD
- +31.79%
- 1 year
- +41.98%
- Market cap
- 9.57B
- EPS (ttm)
- -7.62
- Shares out
- 157.39M
- Forward P/E
- -8.54
- YTD return
- +31.79%
- 1-year return
- +41.98%
- Volume
- 2.18M
- Avg volume
- 2.09M
- Open
- 61.38
- Previous close
- 60.62
- Day's range
- 60.32 – 61.89
- 52-week range
- 39.87 – 90.75
- Beta
- 1.29
- Analysts
- Strong Buy
- Price target
- 117.30 (+92.9%)
- Earnings date
- Nov 3, 2026
5D +1.11 (+1.87%)
Key statistics
- Enterprise value
- 7.65B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -485.76M
- Total cash
- 1.49B
- Total debt
- 115.44M
- Return on equity
- -36.51%
- Short % of float
- 9.34%
- 50-day average
- 61.56
- 200-day average
- 57.10
Analyst view
Consensus: strong buy
- Target (low)
- 75.00
- Target (mean)
- 117.30
- Target (high)
- 163.00
- Strong buy1
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -2.11.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -2.11 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -2.06 | -1.97 | +0.09 | +4.37% |
| May 6, 2026 | Mar 31, 2026 | -1.78 | -2.30 | -0.52 | -29.40% |
| Feb 24, 2026 | Dec 31, 2025 | -1.53 | -1.80 | -0.27 | -17.67% |
| Nov 4, 2025 | Sep 30, 2025 | -1.27 | -1.56 | -0.29 | -22.83% |
| Aug 6, 2025 | Jun 30, 2025 | -1.12 | -1.22 | -0.10 | -8.93% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Oct 5, 2026 | BTIG | reit | Buy | Buy |
| Oct 5, 2026 | Needham | main | Buy | Buy |
| Oct 5, 2026 | Guggenheim | main | Buy | Buy |
| Sep 28, 2026 | B of A Securities | main | Buy | Buy |
| Sep 25, 2026 | Needham | reit | Buy | Buy |
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vaxcyte.com
News
Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? 
Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated “Moderate Buy” by Sell-Side Brokerages 
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet 
Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target 
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…' 
Vaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock sale 
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally 
Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Company Stock 
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes 
Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027
Your note
Sign in to keep a note on PCVX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COWAN ELVIA | Officer | Sale | Oct 4, 2026 | 27,860 |
| DHALIWAL HARPREET S. | Officer | Sale | Aug 4, 2026 | 76,756 |
| EYDELMAN MIKHAIL | General Counsel | Sale | Mar 4, 2025 | 41,620 |
| GUGGENHIME ANDREW | President | Sale | Aug 2, 2026 | 167,026 |
| JODAR LUIS | Officer | Stock Award(Grant) | Sep 3, 2026 | 52,632 |
| LOXAM TERI | Director | Stock Award(Grant) | Jun 14, 2026 | 12,481 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.01% | 20,852,907 | 1.27B | Jun 29, 2026 |
| Jupiter Topco LLC | 12.07% | 17,965,847 | 1.09B | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 8.20% | 12,207,450 | 742.34M | Jun 29, 2026 |
| Blackrock Inc. | 8.11% | 12,068,129 | 733.86M | Jun 29, 2026 |
| RA Capital Management, L.P. | 7.71% | 11,474,599 | 697.77M | Jun 29, 2026 |
| Wellington Management Group, LLP | 4.71% | 7,001,565 | 425.77M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.08% | 4,587,918 | 278.99M | Jun 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 2.69% | 4,007,229 | 243.68M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.29% | 3,411,349 | 207.44M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.23% | 3,312,950 | 201.46M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 2.11% | 3,145,705 | 191.29M | Aug 30, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 1.80% | 2,676,774 | 162.77M | Jun 29, 2026 |